Both the FDA and EMA have suspended Ixchiq’s use in older adults after post-marketing serious adverse events that include two ...

The decision follows ongoing investigations into serious adverse events primarily reported in elderly individuals who ...

FDA and CDC recommend halting Ixchiq vaccine use in adults 60 and older after reports of serious adverse events, including ...

Valneva (VALN) stock is in focus as the U.S. recommends a pause in the company's chikungunya vaccine Ixchiq in adults 60+ ...

Reports of severe adverse events in some people who received the chikungunya vaccine have spurred regulators in Europe and ...

On the heels of similar moves in France and the European Union, U.S. health authorities are calling for a pause in the use of ...

The FDA and CDC have also recommended pausing the use of Ixchiq in seniors 60 years and older while safety investigations are ...

The U.S. government is advising that international travelers age 60 and older not get a chikungunya vaccine as it ...

The use of Valneva’s chikungunya vaccine, known under the brand name Ixchiq, has been paused in elderly individuals after reports of serious adverse events (AEs) The US Food and Drug ...

The FDA and CDC recommended a pause for Ixchiq, a chikungunya vaccine, following reports of adverse events in recipients 60 ...

The U.S. health officials have recommended a pause in the use of French biotech Valneva’s (NASDAQ:VALN) chikungunya vaccine Ixchiq for those aged 60 years and older amid an ongoing safety review ...